Survival
The Mesothelioma Systemic Inflammation Score Is Independently Associated with Overall Survival and Predicts Benefit of Multimodality Treatment in Pleural Mesothelioma
Cancers 2025 April 20 [Link] Berta Mosleh, Katharina Sinn, Anna Cho, Anton Reiner, Ariane Steindl, Christian Lang, Sabine Zöchbauer-Müller, Karin Dieckmann, Joachim Widder, Helmut Prosch, Balazs Dome, Karin Schelch, Clemens Aigner, Thomas Klikovits, Michal Benej, Stefan Watzka, Martin Filipits, Servet Bölükbas, Pavla Sarova, Daniela Gompelmann, Michael Grusch, Mir Alireza Hoda Abstract Background/objectives: Malignant pleural mesothelioma…
Read MoreImmunotherapy in mesothelioma – systematic review and meta-analysis of immunotherapy impact on OS and its correlation with PFS and ORR
Journal of Chemotherapy 2025 April 22 [Link] Marko Skelin, Kaja Matić, Andrea Anić-Matić, Ivan Krečak, Bruna Perkov-Stipičin, Mirko Grubor Abstract Mesothelioma has a poor prognosis, with a 5-year overall survival (OS) rate less than 5%. Immunotherapy has been proven as a promising alternative to platinum-based therapies in first-line treatment. Our systematic literature search included 7…
Read MoreEfficacy and safety of bintrafusp alfa evaluated in a phase II single-arm clinical trial in previously treated advanced pleural mesothelioma
Lung Cancer 2025 May [Link] Ernest Nadal, Paloma Martín-Martorell, Jose Carlos Benítez, Maria Ángeles Sala, Susana Cedrés, Carlos Álvarez, Manuel Dómine, Elia Sais 8, Maria Saigí, Rafael López, Laia Vilà, Bartomeu Massutí, Rosario García-Campelo, Andres Mesas-Ruiz, Amelia Insa, Sílvia Plans-Marín, Sara Hijazo-Pechero, Cristina Muñoz-Pinedo, Jesús Brenes, Mariano Provencio Abstract Objectives: We aimed to evaluate the…
Read MoreRadical hemithorax radiotherapy induces an increase in circulating PD-1+ T lymphocytes and in the soluble levels of PD-L1 in malignant pleural mesothelioma patients: a possible synergy with PD-1/PD-L1 targeting treatment?
Frontiers in Immunology 2025 April 1 [Link] Alberto Revelant, Francesca Gessoni, Marcella Montico, Raja Dhibi, Giulia Brisotto, Mariateresa Casarotto, Martina Zanchetta, Veronica Paduano, Filippo Sperti, Chiara Evangelista, Fabiana Giordari, Valli De Re, Marco Trovò, Emilio Minatel, Maurizio Mascarin, Agostino Steffan, Elena Muraro Abstract Malignant Pleural Mesothelioma (MPM) is an aggressive tumor associated with asbestos exposure,…
Read MoreIncidence and Outcomes of Brain Metastasis in Pleural Mesothelioma in the Era of Immunotherapy
JTO Clinical & Research Reports 2025 March 10 [Link] Margaret Stalker, Suzanne L Walker, Emily Lebow, Emily Ling-Lin Pai, Alex Watts, Wei-Ting Hwang, Amir Banihashemi, Evan Anderson, Leonid Roshkovan, Sharyn I Katz, Leslie Litzky, Andrew R Haas, Sunil Singhal, Corey J Langer, Keith Cengel, Melina E Marmarelis Abstract Introduction: Immunotherapy (IO) has reported efficacy in…
Read MoreHyperthermic intrathoracic chemotherapy in patients with malignant pleural mesothelioma after cytoreductive surgical procedures: a systematic review
World Journal of Surgical Oncology 2025 April 9 [Link] Hany Hasan Elsayed, Mohamed Elanany Elsaid Elanany, Mohamed Tarek ElSayegh, Aly Sherif Hassaballa, Mohammed Abdel-Gayed Abstract Surgery-based multimodality therapies for treatment of malignant pleural mesothelioma have been clinically explored in the past decades. In this regard, hyperthermic intrathoracic or intrapleural chemotherapy has been used as one…
Read MorePD-L1 pfeRNAs as blood-based predictors of treatment response of unresectable malignant pleural mesothelioma patients administered Durvalumab with cisplatin and pemetrexed as first-line therapy
Non-Coding RNA Research 2025 February 21 [Link] Andrei Gurau, Suguru Yamauchi, Kaitlyn Ecoff, Kristen P Rodgers, James R Eshleman, Charles Conover Talbot Jr, Peng Huang, Joshua Choi, Patrick M Forde, Valsamo Anagnostou, Malcolm Brock, Yuping Mei Abstract Background: A new therapeutic avenue combining Durvalumab with cisplatin-pemetrexed (Durva-CP) has delivered a promising outcome for previously untreated…
Read MoreDevelopment and validation of a prognostic nomogram for patients with malignant peritoneal mesothelioma
Frontiers in Oncology 2025 February 28 [Link] Xiaohan Wang, RuiTing Liu, Chunli Wang, Jingjing Sun, Dongliang Yang Abstract Background: Malignant peritoneal mesothelioma(MPM) is a highly aggressive malignant tumor that originates from peritoneal mesothelial cells. Due to the rarity of MPM, there are few survival prediction models specifically for visualization of malignant peritoneal mesothelioma. Objective: This…
Read MorePrognostic Value of Chest CT Volumetric Analysis in Patients with Malignant Pleural Mesothelioma
Journal of Clinical Medicine 2025 February 25 [Link] Elisa Baratella, Eleonora Ercolani, Antonio Segalotti, Marina Troian, Stefano Lovadina, Fabiola Giudici, Pierluca Minelli, Barbara Ruaro, Francesco Salton, Maria Assunta Cova Abstract Background/Objectives: Malignant pleural mesothelioma (MPM) is a rare, aggressive cancer linked to asbestos exposure and with poor overall survival. In recent years, CT volumetric analysis…
Read MoreClinical Significance of Bone Metastases in Pleural Mesothelioma
Thoracic Cancer 2025 March [Link] Mitsutomi Miyake, Kozo Kuribayashi, Hiroshi Doi, Aki Kubota, Taiichiro Otuski, Yoshiki Negi, Koji Mikami, Ryo Takahashi, Akifumi Nakamura, Yasuhiro Nakajima, Daichi Fujimoto, Kazuhiro Kitajima, Toshiyuki Minami, Takashi Kijima Abstract Background: Bone metastasis (BoM) is common in advanced cancer, but its incidence in pleural mesothelioma (PM) remains unclear. This study aimed…
Read More